


Recognizing Cardiac Manifestations of Transthyretin Amyloidosis (ATTR)¹

			
<p>CLINICAL</p> <ul style="list-style-type: none"> • Shortness of breath² • Edema² • Palpitations and arrhythmias² • Fatigue • Heart failure symptoms • Family history of heart failure • Orthostatic hypotension² 	<p>IMAGING</p> <ul style="list-style-type: none"> • Increased left ventricular wall thickness • Grade 2 or worse diastolic function • Abnormal longitudinal strain with apical sparing • Diffuse subendocardial or transmural LGE on CMR imaging with increased extracellular volume fraction 	<p>ELECTRICAL</p> <ul style="list-style-type: none"> • Conduction system disease/pacemaker • Atrial fibrillation • Pseudoinfarct pattern • Discordant QRS voltage for degree of increased left ventricular wall thickness on imaging 	<p>LABORATORY</p> <ul style="list-style-type: none"> • Persistent low-level troponin elevation • Elevated B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide

ACC 2023 Diagnostic Algorithm for ATTR¹



^{99m}Tc-PYP, technetium-99m pyrophosphate; ACC, American College of Cardiology; AL-CM, monoclonal immunoglobulin light-chain amyloidosis with cardiomyopathy; ATTR, transthyretin amyloidosis; ATTR-CM, transthyretin amyloidosis with cardiomyopathy; CMR, cardiac magnetic resonance; ECG, electrocardiogram; hATTR, hereditary transthyretin amyloidosis; IFE, immunofixation electrophoresis; LGE, late gadolinium enhancement; PYP, pyrophosphate; wtATTR, wild-type transthyretin amyloidosis.

1. Kittleson MM, et al. *J Am Coll Cardiol.* 2023;81(11):1076-1126; 2. Adams D, et al. *Orphanet J Rare Dis.* 2021;16:411.


Developed by Alnylam Pharmaceuticals, Inc. This resource is for educational purposes only. The information provided is not intended to serve as recommendations for clinical practice.

©2025 Alnylam Pharmaceuticals, Inc. All rights reserved. MED-US-DZSTATE-2300056.

Recognize Extracardiac Manifestations of ATTR Due to Toxic Fibril Deposition¹

MUSCULOSKELETAL	SENSORY-MOTOR NEUROPATHY	AUTONOMIC DYSFUNCTION	GASTROINTESTINAL MANIFESTATIONS ^a
<ul style="list-style-type: none"> Bilateral carpal tunnel syndrome Biceps tendon rupture Lumbar spinal stenosis Shoulder, knee, and hip pain or surgery Trigger finger 	<p>Sensory symptoms (Early manifestation)</p> <ul style="list-style-type: none"> Numbness and tingling Altered sensation (change in sensitivity to pain or temperature) Impaired balance/falls <p>Motor loss (Late manifestation)</p> <ul style="list-style-type: none"> Muscle weakness Tripping, foot drop Difficulty walking or with stairs 	<ul style="list-style-type: none"> Orthostatic hypotension Diarrhea or constipation Urinary retention (recurrent UTI)² Erectile dysfunction 	<p>Mucosal</p> <ul style="list-style-type: none"> Malabsorption: bloating, nausea, vomiting, diarrhea <p>Neuropathic</p> <ul style="list-style-type: none"> GI dysmotility: bloating, nausea, vomiting, diarrhea, constipation, gastroparesis,³ and early satiety³ <p>Vascular</p> <ul style="list-style-type: none"> GI bleeding, ischemia

Diagnosing Suspected hATTR with Polyneuropathy⁴



Adapted from Karam C, et al. 2024⁴

^aGI symptoms may be difficult to attribute to GI amyloid deposition as cardiac involvement and medication side effects may also cause abdominal pain, nausea, diarrhea, or constipation.

^bPatients may be assessed for genetic conditions including Charcot-Marie-Tooth disease and hereditary neuropathy with liability to pressure palsies, or screened for vitamin B12 deficiency, diabetes (hemoglobin A1C assessment), thyroid dysfunction, monoclonal gammopathy (immunofixation electrophoresis), or AL amyloidosis (immunoglobulin free light chain assessment).

^cImportance of tissue diagnosis is greater when concurrent possible causes of peripheral neuropathy (ie, B12 deficiency, diabetes mellitus, paraproteinemia, etc) are present. In certain cases where there is no alternative cause for a progressive neuropathy, especially when multisystem features are present, a biopsy may not be necessary. A negative tissue biopsy in a patient with a high suspicion of hATTR does not exclude a diagnosis, and further investigation (ie, scintigraphy) or close follow-up is warranted.

AL, amyloid light chain; **ATTR**, transthyretin amyloidosis; **CTS**, carpal tunnel syndrome; **GI**, gastrointestinal; **hATTR**, hereditary transthyretin amyloidosis; **NT-proBNP**, N-terminal pro-brain natriuretic peptide; **PYP**, pyrophosphate; **TTR**, transthyretin; **UTI**, urinary tract infection; **wtATTR**, wild-type transthyretin amyloidosis.

1. Kittleson MM, et al. *J Am Coll Cardiol*. 2023;81(11):1076-1126; 2. Bentellis I, et al. *Clin Auton Res*. 2019; 29(Suppl 1):S65-S74; 3. Adams D, et al. *Orphanet J Rare Dis*. 2021;16:411; 4. Karam C, et al. *Muscle Nerve*. 2024;69(3):273-287.